MGMT promoter methylation and hypermutant recurrence in IDH mutant lower-grade glioma

被引:6
|
作者
Miller, Julie J. [1 ,2 ]
Cahill, Daniel P. [1 ,3 ]
机构
[1] Harvard Med Sch, Massachusetts Gen Hosp, Translat Neurooncol Lab, Boston, MA 02115 USA
[2] Harvard Med Sch, Massachusetts Gen Hosp, Div Neurooncol, Dept Neurol, Boston, MA 02115 USA
[3] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02115 USA
关键词
glioma; IDH1; mutation; temozolomide; TEMOZOLOMIDE; PROCARBAZINE; VINCRISTINE; PROGRESSION; LOMUSTINE; EVOLUTION; THERAPY; BENEFIT;
D O I
10.1093/neuonc/noaa212
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:1553 / 1554
页数:2
相关论文
共 50 条
  • [11] Accelerated progression of IDH mutant glioma after first recurrence
    Miller, Julie J.
    Loebel, Franziska
    Juratli, Tareq A.
    Tummala, Shilpa S.
    Williams, Erik A.
    Batchelor, Tracy T.
    Arrillaga-Romany, Isabel
    Cahill, Daniel P.
    NEURO-ONCOLOGY, 2019, 21 (05) : 669 - 677
  • [12] Shorting vorasidenib for IDH mutant low-grade glioma
    Wong, Eric T.
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2024, 9 (01): : 1 - 2
  • [13] Favorable role of IDH1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma
    Pandith, Arshad A.
    Qasim, Iqbal
    Baba, Shahid M.
    Koul, Aabid
    Zahoor, Wani
    Afroze, Dil
    Lateef, Adil
    Manzoor, Usma
    Bhat, Ina A.
    Sanadhya, Dheera
    Bhat, Abdul R.
    Ramzan, Altaf U.
    Mohammad, Fozia
    Anwar, Iqra
    FUTURE SCIENCE OA, 2021, 7 (03):
  • [14] Prognostic and predictive impact of MGMT promoter methylation status in high risk grade II glioma
    Haque, Waqar
    Teh, Caitlyn
    Butler, E. Brian
    Teh, Bin S.
    JOURNAL OF NEURO-ONCOLOGY, 2022, 157 (01) : 137 - 146
  • [15] TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data
    Huy Gia Vuong
    Altibi, Ahmed M. A.
    Duong, Uyen N. P.
    Ngo, Hanh T. T.
    Thong Quang Pham
    Chan, Aden Ka-Yin
    Park, Chul-Kee
    Fung, Kar-Ming
    Hassell, Lewis
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 120 : 1 - 9
  • [16] An independently validated survival nomogram for lower-grade glioma
    Gittleman, Haley
    Sloan, Andrew E.
    Barnholtz-Sloan, Jill S.
    NEURO-ONCOLOGY, 2020, 22 (05) : 665 - 674
  • [17] Prognostic significance of MGMT promoter methylation in diffuse glioma patients
    Jovanovic, Nikola
    Mitrovic, Tatjana
    Cvetkovic, Vladimir J.
    Tosic, Svetlana
    Vitorovic, Jelena
    Stamenkovic, Slavisa
    Nikolov, Vesna
    Kostic, Aleksandar
    Vidovic, Natasa
    Jevtovic-Stoimenov, Tatjana
    Pavlovic, Dusica
    BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT, 2019, 33 (01) : 639 - 644
  • [18] Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma
    Cheng, Wen
    Li, Mingyang
    Jiang, Yang
    Zhang, Chuanbao
    Cai, Jinquan
    Wang, Kuanyu
    Wu, Anhua
    JOURNAL OF NEUROSURGERY, 2016, 125 (01) : 7 - 16
  • [19] Combined IDH1 mutation and MGMT methylation status on long-term survival of patients with cerebral low-grade glioma
    Tanaka, Kazuhiro
    Sasayama, Takashi
    Mizukawa, Katsu
    Takata, Kumi
    Sulaiman, Nor Shazrina
    Nishihara, Masamitsu
    Kohta, Masaaki
    Sasaki, Ryohei
    Hirose, Takanori
    Itoh, Tomoo
    Kohmura, Eiji
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2015, 138 : 37 - 44
  • [20] The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents
    Kurdi, Maher
    Butt, Nadeem Shafique
    Baeesa, Saleh
    Alghamdi, Badrah
    Maghrabi, Yazid
    Bardeesi, Anas
    Saeedi, Rothaina
    Al-Sinani, Taghreed
    Alghanmi, Najla
    Bari, Mohammed O.
    Samkari, Alaa
    Lary, Ahmed, I
    PATHOLOGY & ONCOLOGY RESEARCH, 2021, 27